Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers

Annals of Clinical Biochemistry
S ManleyJ M Smith

Abstract

To review 'Diabetes Control and Complications Trial (DCCT)-aligned' HbA(1c) reporting in UK, use of individual/network equations relating IFCC calibration to 'DCCT alignment', and whether HbA(1c) in the presence of variant haemoglobins is, according to manufacturers, suitable for current, clinical guidelines. Questionnaire sent to nine manufacturers and responses analysed. All methods were certified as 'DCCT-aligned' by National Glycohemoglobin Standardization Program (NGSP); UK EQA schemes reported 95% of results 'DCCT-aligned' in December 2004. The master equation relating networks was used by six manufacturers and specific equations for individual methods by three. HbA(1c) results from laboratory/point of care testing analysers can be affected by variant haemoglobins including elevated HbF; only IE HPLC (and LPLC) detect their presence. If chromatographic separation is ideal in heterozygous patients, laboratories either choose not to report HbA(1c) and propose another strategy for monitoring glycaemia, or report HbA(1c) and issue a caution that it may not be appropriate for guidelines. HbA(1c) reported from immunochemistry or affinity chromatography in presence of variant haemoglobins, may not be reliable for use with clinic...Continue Reading

Citations

Feb 23, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·S E Manley
Jun 23, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Kristina Jackson BehanHong-Kee Lee
Mar 21, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·C M BennettS C Dharmage
Mar 17, 2007·Clinical Chemistry·Susan E ManleyStephen D Luzio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.